• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖对茶碱表观分布容积的影响。

The effect of obesity on apparent volume of distribution of theophylline.

作者信息

Rohrbaugh T M, Danish M, Ragni M C, Yaffe S J

出版信息

Pediatr Pharmacol (New York). 1982;2(1):75-83.

PMID:7110759
Abstract

An oral theophylline product was given to eight lean, normal subjects and eight obese subjects (four with asthma and four normals) in a single-dose study. The mean apparent volume of distribution (Vd) was 0.472 +/- 0.08 liters/kg for the lean group and 0.321 +/- 0.063 liters/kg for the obese group (P less than 0.001). When Vd wax expressed in liters, there was no difference between the two groups (lean:26.9 +/- 6.0 liters, obese: 28.5 +/- 6.3 liters). An inverse relationship existed between the ratio of total body weight to ideal body weight (TBW/IBW) and Vd expressed in liters/kg. One obese subject was studied before and after a weight loss of about 32 kg. The values of Vd in this subject were 32.1 and 34.9 liters, respectively. These data indicated that theophylline is not extensively distributed into adipose tissue and that loading-dose calculations should be based on ideal body weight. No difference in clearance of theophylline was seen between the two groups.

摘要

在一项单剂量研究中,给8名瘦的正常受试者和8名肥胖受试者(4名哮喘患者和4名正常人)服用了一种口服茶碱产品。瘦组的平均表观分布容积(Vd)为0.472±0.08升/千克,肥胖组为0.321±0.063升/千克(P<0.001)。当Vd以升为单位表示时,两组之间没有差异(瘦组:26.9±6.0升,肥胖组:28.5±6.3升)。总体重与理想体重之比(TBW/IBW)与以升/千克表示的Vd之间存在反比关系。对一名肥胖受试者在体重减轻约32千克前后进行了研究。该受试者的Vd值分别为32.1升和34.9升。这些数据表明,茶碱不会广泛分布到脂肪组织中,负荷剂量的计算应基于理想体重。两组之间茶碱的清除率没有差异。

相似文献

1
The effect of obesity on apparent volume of distribution of theophylline.肥胖对茶碱表观分布容积的影响。
Pediatr Pharmacol (New York). 1982;2(1):75-83.
2
Theophylline disposition in obesity.肥胖患者体内茶碱的处置情况
Clin Pharmacol Ther. 1978 Apr;23(4):438-44. doi: 10.1002/cpt1978234438.
3
Influence of body fat on the volume of distribution of theophylline.体脂对茶碱分布容积的影响。
Ther Drug Monit. 1985;7(2):197-201. doi: 10.1097/00007691-198506000-00010.
4
Digoxin disposition in obesity: clinical pharmacokinetic investigation.肥胖患者中地高辛的处置:临床药代动力学研究。
Am Heart J. 1981 Oct;102(4):740-4. doi: 10.1016/0002-8703(81)90100-9.
5
Effect of body weight on the volume of distribution of theophylline.体重对茶碱分布容积的影响。
Lung. 1988;166(5):269-76. doi: 10.1007/BF02714057.
6
Volume of distribution of theophylline in acute exacerbations of reversible airway disease. Effect of body weight.氨茶碱在可逆性气道疾病急性加重期的分布容积。体重的影响。
Chest. 1985 Feb;87(2):212-6. doi: 10.1378/chest.87.2.212.
7
Theophylline clearance: effect of marked obesity.茶碱清除率:显著肥胖的影响。
Clin Pharmacol Ther. 1980 Nov;28(5):619-23. doi: 10.1038/clpt.1980.212.
8
Carbamazepine pharmacokinetics in obese and lean subjects.肥胖与消瘦受试者的卡马西平药代动力学
Ann Pharmacother. 1995 Sep;29(9):843-7. doi: 10.1177/106002809502900902.
9
Cimetidine disposition in obesity.肥胖患者中西咪替丁的处置情况。
Am J Gastroenterol. 1984 Feb;79(2):91-4.
10
Obesity effects on nitrazepam disposition.肥胖对硝西泮处置的影响。
Br J Clin Pharmacol. 1986 Nov;22(5):551-7. doi: 10.1111/j.1365-2125.1986.tb02934.x.

引用本文的文献

1
Cross-validation for nonlinear mixed effects models.非线性混合效应模型的交叉验证。
J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):243-52. doi: 10.1007/s10928-013-9313-5. Epub 2013 Mar 27.
2
Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.内源性和外源性效应物对茶碱药代动力学的影响。重点关注生物转化。
Clin Pharmacokinet. 1995 Apr;28(4):287-314. doi: 10.2165/00003088-199528040-00003.
3
Caffeine disposition in obesity.肥胖人群中的咖啡因代谢情况
Br J Clin Pharmacol. 1985 Jul;20(1):61-6. doi: 10.1111/j.1365-2125.1985.tb02799.x.
4
Drug disposition in obese humans. An update.肥胖人群中的药物处置。最新进展。
Clin Pharmacokinet. 1986 May-Jun;11(3):199-213. doi: 10.2165/00003088-198611030-00002.
5
Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.体重对乳腺癌患者环磷酰胺药代动力学的影响。
Cancer Chemother Pharmacol. 1987;20(3):219-22. doi: 10.1007/BF00570489.
6
Relationship of bioelectrical impedance to pharmacokinetic parameters of theophylline in healthy males.健康男性体内生物电阻抗与茶碱药代动力学参数的关系。
Clin Pharmacokinet. 1989 Sep;17(3):200-7. doi: 10.2165/00003088-198917030-00005.
7
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.由于药物分布改变,肥胖患者异环磷酰胺消除半衰期延长。
Cancer Chemother Pharmacol. 1989;25(2):139-42. doi: 10.1007/BF00692355.